Navigation Links
Vasogen Provides Update on ACCLAIM II Program
Date:3/3/2008

al clinical trials and the size and design of any such trials, delays or setbacks in the regulatory approval process, difficulties in the maintenance of existing regulatory approvals, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors on capital availability, the potential dilutive effects of any financing, risks associated with the outcomes of our preclinical and clinical research and development programs, the adequacy, timing, and results of our clinical trials, competition, market acceptance of our products, the availability of government and insurance reimbursements for our products, the strength of intellectual property, reliance on partners, subcontractors, and key personnel, losses due to fluctuations in the U.S.-Canadian exchange rate, and other risks detailed from time to time in our public disclosure documents or other filings with the Canadian and U.S. securities commissions or other securities regulatory bodies. Additional risks and uncertainties relating to our Company and our business can be found in the "Risk Factors" section of our Annual Information Form and Form 20-F for the year ended November 30, 2007, as well as in our later public filings. The forward-looking statements are made as of the date hereof, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. CardioDynamics Provides 2007 Shareholder Meeting Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... the health of your heart, researchers have discovered. , ... standard TENS machine like those designed to relieve labour ... small raised flap at the front of the ear ... stimulation changed the influence of the nervous system on ... drive failing hearts too hard. , Professor Jim Deuchars, ...
(Date:8/20/2014)... August 20, 2014 GraphDB™ ... today including improvements to the enterprise replication cluster, ... for Lucene, SOLR and Elasticsearch. This release happens ... high performance triplestore – GraphDB™ was formerly known ... deploying the only mature enterprise resilient RDF triplestore ...
(Date:8/19/2014)... Shimadzu Scientific Instruments has introduced two ... adding to the company’s extensive line-up of HPLC ... operating environment, and full automation, the i-Series provides ... conventional to ultra-high-speed analysis. , The ... so users can begin building the lab of ...
(Date:8/19/2014)... 2014 A Geisinger researcher on a personal ... Centers for Disease Control and Prevention (CDC) award recognizing ... concern. Joseph Boscarino , Ph.D. MPH, ... team of researchers nominated for the Centers for Disease ... for Data Methods and Study Design. "Hepatitis ...
Breaking Biology Technology:'Tickling' your ear could be good for your heart 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3
... ChemAxon, a software,solutions provider for cheminformatics today ... cheminformatics toolkits, Marvin & JChem. The release,sees ... enumeration and,core development in JChem search, clustering ... is a suite of application programming interfaces ...
... 16% of U.S. Cardiology Offices ... Importance, SAN DIEGO, Feb. 19 CardioDynamics ... cardiography (ICG),technology, today announced that the Company,s BioZ ... ACCEL audio series., ACCEL is the American ...
... FDA Application for Stem Cell Therapy in SMA,will begin ... Families of,Spinal Muscular Atrophy (FSMA); a stem cell scientist ... Inc. (CSC) are pleased,to announce a partnership to advance ... trials. The specific set of animal studies planned, which,will ...
Cached Biology Technology:ChemAxon Launches Marvin and JChem Version 5: Better User Experience, Better Integration, More Flexibility and Higher Performance 2CardioDynamics BioZ(R) ICG Technology Featured in American College of Cardiology (ACC) Audio Series 2CardioDynamics BioZ(R) ICG Technology Featured in American College of Cardiology (ACC) Audio Series 3Families of Spinal Muscular Atrophy; University of California, Irvine Stem Cell Scientist; and California Stem Cell Announce Collaboration for Safety Studies for Stem Cell Therapy in Spinal Muscular Atrophy 2Families of Spinal Muscular Atrophy; University of California, Irvine Stem Cell Scientist; and California Stem Cell Announce Collaboration for Safety Studies for Stem Cell Therapy in Spinal Muscular Atrophy 3
(Date:8/20/2014)... POINT ROBERTS, Washington , August 20, 2014 ... Role in Addressing Security Concerns in the Payment Industry? ... source covering leading sectors including biometrics, issues commentary from analysts ... Jason Peaslee , Managing Partner at Thrive Analytics, ... Pereira , CEO of NXT-ID, Inc. (OTCBB: NXTD) ( OTCQB:NXTD ...
(Date:8/19/2014)... release is available in German . ... inherently intermittent energy sources. If a large amount of electricity ... future, excess energy will have to be stored during productive ... existing storage capacities are far from adequate for the purpose. ... One important focus lies on battery systems that used to ...
(Date:8/19/2014)... engineers have devised a new implantable tissue scaffold coated ... a few weeks. When applied to bone injuries or ... form new bone that looks and behaves just like ... could offer a dramatic improvement over the current standard ... another part of the patient,s body a painful ...
Breaking Biology News(10 mins):Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 3Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 4Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 5Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 6Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 7Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3Engineering new bone growth 2Engineering new bone growth 3
... - Eurofins MWG Operon, an expert in next generation sequencing ... libraries for sequencing with Roche GS FLX or Illumina HiSeq ... long paired end (LPE) libraries with different jumping distances (3 ... After sequencing, the resulting reads are assembled into large contigs ...
... of a TB Vaccine PDP, An Exhibitor,s Workshop at the ... 1:00-2:00 PM VENUE: 2011 AAAS ANNUAL MEETING, ,WASHINGTON CONVENTION ... an overview of the state of the global TB epidemic ... product development partnerships such as Aeras; and ways that scientists ...
... found attached to the foot of an ancient Egyptian mummy ... parts, says the scientist who tested replicas on volunteers. ... a three-part wood and leather artefact housed in the Egyptian ... Chester artificial toe on display in the British Museum, not ...
Cached Biology News:Mummies' false toes helped ancient Egyptians walk 2
... jetSI-ENDO-FluoF is a ... nm; emission at 520 nm), ... These reagents are used to ... investigate the intracellular delivery and ...
... R&D Systems Cell and Tissue Staining ... in a broad range of histological and ... with primary IgG antibodies manufactured by either ... detection is based on the formation of ...
... Protein Purification Protocols covers a wide ... for novice and experienced researchers in all ... This excerpt from the books preface illustrates ... to your research library., The chapters introduce ...
... Definitive Performance The TSQ ... quantitation excellence in bioanalytical and environmental analysis. ... source ESI and APCI probes, a titanium ... for increased robustness and sensitivity. Its ...
Biology Products: